Thank you, Len.
with With efforts will the COVID-XX pandemic, targeting REGEN-COV, world start our of I on in still our throes the virus. the cocktail antibody the SARS-CoV-X
recently criteria antibody achieved important in REGEN-COV in In the on received EUA cocktail we risk in results in moderate COVID-XX study hospitalized patients continue mild initial to for associated risk announced we encouraging the December, non-hospitalized based successfully being high or the flow have mechanical passing milestones. patients. oxygen, The with of patients with granted treatment Over our the November use death and XX, setting. large ventilation. last on low was initial several a reduction results cocktail On authorization FDA emergency to diagnosed in months, the from few
Just infections capable XXX% the last shedding in month, and be infectious with initial of be showed of virus. expected high patients and of viral reduction which transmitting symptomatic setting, the released prevention duration to prevention we XXX% COVID-XX when would most of REGEN-COV the data
our Importantly, is dose, were using delivery. these subcutaneous results simplified achieved lower which
Phase of in demonstrating important issue in prospectively for the hospitalized to populations patient as additional the These have emerging mind. the recovery broader upcoming results cocktail the setting of the collaboration across lower study. both are our terms datasets as report variants of designed in efficacy an and to supporting confirmatory immunity. important and variants, We part have address our vaccine-derived in I expect next the want the with setting, regulatory few outpatient readouts dominated setting evade with potential which includes natural UK worldwide. as which in our over virus of evaluation approvals they as well such to months dose, III We prevention news the
that match the that of States. potential academics. mutation of prospective our variants, hope mix be in was active these against journal, against as fact, confirmed efficiently in needed, the time widespread intelligent of African Science cocktails currently that we have all variants. virus cocktail future In variants been South withstand as could about approach, by known have current anticipated and Brazilian emerging collection in course, immunity large rapidly will antibody and and exact new we and Because raising a seen and the resistance of immunity, of to now recently create variants. of independently back will we ready our If United recognition this is We, threats the viral prominent design in in June, variants also the concerns published our multiple also for antibody is vaccines that challenge
is indicate a immunity. up be individuals to to according emerging against die vaccines successfully However, to vaccines widespread already even immunity point. that long until XX% if loss vaccine reach Moreover, REGEN-COV the optimistic Recent believe the data thousands that it new the approaches, threat the further effective undermine we than with and of strategic and antibody prevalence. hundreds antibody the as posing both immunity. estimated variants, in ongoing lasting most provide such months, real deployment life may new way efficacy natural well such next and very the possibility may disease tragically waning vaccine of timeline, provide less targeted as of of six are derived mutations over our as so of could reduce vaccine We a to potential as be having to protection cocktail, against the to variants
indications of potential are trials new inflammation notably, presented last in Recall part to portfolio, A we Moving our data III Most in and Dupixent multiple year. that now quickly. from immunology Phase fully progressing is study eosinophilic that esophagitis has encouraging the Dupixent enrolled. in trial our
could published be pulmonary As are we our and concept in COPD, chronic in part enrolling smokers we that IL-XX year, treating against study our where COPD started have seen obstructive outlined confirmatory ongoing the We recently, of later exacerbations. Type we Sanofi Dupixent imminently. III or now believe disease Phase to patients. a III Phase along antibody. Phase of a this this in Phase III Based is that of in blocking Itepekimab former two-pronged The proof with useful be first have data patients, on COPD studies study will Dupixent II two and anti-IL-XX also Itepekimab, COPD approach X our with begin reduction of subset for XX%
for allergic is this hope desensitize suffering inhaled program diseases. and can food approaches so-called benefits individuals from in options and particular, additional patients the to many COPD efforts broad multiple part allergens. from to Our Itepekimab of Dupixent treat is Dupixent and no biologic to date. also for In provide with real
to with will results protein allergy allergy, that of desensitization unsatisfying announce and of secondary alone. trial immunotherapy the II this oral a in met know, with desensitization millions when steps patients inform of data allergy Therapeutics' allergy undergoing Dupixent patients year well. to placebo-controlled monotherapy I with desensitization years combination Aimmune later pleased of immunotherapy after coupled results, showing As Phase peanut each separate key endpoints, are you Dupixent peanut to with that even often treatments. in II Phase for next in improved These primary this pediatric as allergy am setting its and significantly oral with forms from compared year, other trial peanut
to approaches allergy. We also have new additional groundbreaking
directed We bind neutralize directly allergens antibodies the these to the antibody-based first can idea that created themselves, have therapeutics allergens. with the and
seasonal Our allergies and first be patients and concomitant allergies allergy And of cat the patients therapies cause other allergy these may allergy, are with two the with for important target in for birch desensitization. birch particularly anti-allergen with asthma candidates spring. antibodies these since not being major
open conducted at our the studies expected data be have will field of showing potential these anti-allergen detailed We for III revolutionize that with study presenting be from concept now throughout this proof season, will upcoming and first treatment birch the is results Phase enrollment to year. the in paradigm. antibodies algae later meetings, And allergy
suffering similarly from later III study year. Phase patients planning in this allergy cat We begin a to are
that briefly We of attempts profile to real at I'd last efficacy appreciate advantages. as near-term leading And and of that EYLEA any Next, have accumulated XX with challenge have We safety would have numbers myriad clinical like withstood its discuss to treated injections. has longer that we over remind patients world the experience EYLEA. decade intervals over you like suggesting competitors to be effectively not EYLEA. clear is it substantial important that can data shown trials million
of ALTAIR to study a patients interval. the example, extended XX% can XX-week For be that shows about treatment
hope EYLEA that now with and allow program are enrolling can be more the to We safety which even high-dose patients we deliver efficacy our same Phase III extended.
carcinoma. for chemotherapy FDA conducting In Data label lung and study Safety positive Later action, Libtayo non-small in in in be basal with starting cervical and to cell cancer. a lung assuming for matter a second interim expansions Libtayo cell Monitoring expect oncology for cancer study Moving will our of weeks, in line Independent cancer year, significant Committee and we the efforts, this two combination analyses our Libtayo. monotherapy
as with a cancer meeting more. as well to CDX a our lymphomas. bispecifics December continue presented This x portfolio for to emerging continued all and with of to responses a itself non-melanoma combination two of we space foundational be and it which bispecific, bispecifics major that Society rates as at both combinations our we well focus we're in Hematology, ASH, the as in each other, Libtayo, strategy the for as leaders it our as leading update on these of Odronextamab, exploring We paired with bispecifics combinations American cancers, the or up high as show player CDXX the durable for as costim new powerful make therapy cytokine new step to minimize events to cancers dosing formulation We diffuse progress and the establishing protocol immunotherapy in so-called A with lung designed under These major follicular Libtayo oncology the as already are novel on are hope employ bringing development as large CDX as as subcutaneous FDA and classes potential has to is our can approach to many it skin make treatments. desperate classes bispecifics. we We're release B well. cell this phase optimal is further syndrome with working during dosing agent. determine the rare of
refractory ASH at as start subcutaneous relapsed this year. formulation year our as as bispecifics enrollment full trials BCMA this also anticipated updates provided also on III pivotal We studies x CDX Phase well And program, our is are with this well. Phase myeloma. on trial to for II well, for track a of enrolling
cancer, bispecific, Our for in signals. observing bispecific ovarian MUCXXxCDX trials third we CDX REGNXXXX, dose clinic, the efficacy thoroughly are our continues escalation where in
MUCXXxCDXX will dosed it with Later will its patient bispecific trial generalizable pairing are of costimulatory year, in our making also solid approach combined Libtayo. as also Notably, has Our as for which combination provide our CDX will bispecific, this continue first we patients in MUCXXxCDX and and well a first and our with bispecific, it our hematologic bispecifics costim be game-changing progressing. costim tumors. hope for clinical to just
bispecific costim with this to bispecific later CDXXxCDX costim we a with will in BCMAxCDX of for of paired our lymphoma. bispecific And to bispecific soon be latter, be trials be our a the different initiating Regarding paired myeloma. year,
with patients escalation trials progressing EGF a is costim costim Libtayo the pairing with potential targeting programs synergistically bispecific also and allow cancer. has a bispecs anti-PD-X the that combination the immunooncology more each other for PCMA we for prostate have These variety treatments. will of well. as unleash our power than with in approved combinations receptor novel And to with Our dose of broadly currently
results appreciate careful such, system line trials powerful possible top there drugs hope We in for safety, combination in timing interest XXXX. announcements designed while lot are and is in ensure these to pathways. and XXXX, readouts or are requirement deliberate early to escalation releases programs. are data a to data patient's these of early from you as As Hence, patient dose occur novel the and equally the activate immune involve of possible the
help that, this like homozygous we known builds for addition Beyond Evkeeza, and rare to as cardiometabolic approval potential I'd expect familial for disease. highlight oncology, patients from If week, portfolio now approved, the this next our evinacumab, hypercholesterolemia. our to upon has to suffering expertise,
it finish, highlight human to our Medicines believe could be I introduced marketing validating others. at Initiative, XXXX, Alnylam, continue collaborations for entire identifying industry. and we only authorizations. new therapies our partners transformational, we like our two Regeneron, Regeneron Decibel, the Genetics Intellia, Center, bluebird, for six nine secured in new as pivotal that for sequencing for submitted Before and into such targets investigational applications which already drug for And To to was we new I'd involves which to but conclude, and important our efforts in indications clinic, the with not Genetics approvals invest and world-leading have partners new
We are investigators have thank achieved been remarkable proud Regeneron like With that, these essential patients accomplishments. I'd has the And to Marion. difficult of we a to many team year. it who with our to us helping turn in and our accomplishments over
